Full Text Hide / show
Introduction
Directive Publications Hussein Naji Abdullah Alshammari GRAPHICAL ABSTRACT 2026 IRON-DEFICIENCY ANEMIA Iron-deficiency anemia (IDA) constitutes a widespread public health concern that impacts billions of individuals globally, resulting in numerous health complications and economic repercussions [1], the objective of this review paper is to offer a thorough background regarding IDA, its worldwide impact, and the diverse strategies utilized to tackle this critical issue. IDA is defined by a reduction in red blood cell count or a decline in the blood's hemoglobin, stemming from an insufficient iron supply.[2] Iron serves as a vital micronutrient in multiple physiological processes, such as oxygen transport, energy production, and immune function [3]. IDA represents the most prevalent type of anemia, comprising roughly 50% of all anemia cases [4]. It is a multifactorial condition, with causes spanning from inadequate diet, malabsorption, and blood loss to genetic factors and infections [5]. IDA impacts over 1.6 billion individuals worldwide, and its prevalence is greatest in developing nations, where approximately 50% of preschool-aged children and pregnant women are affected.[4] Though it occurs less frequently in developed nations, IDA continues to represent a substantial public health issue, especially among women of childbearing age and individuals from low-income backgrounds.[5] Vulnerable groups, such as children, women of reproductive age, and pregnant women, are affected by IDA at disproportionate rates [6]. Among children, IDA may result in impaired cognitive development, weakened immune function, and heightened vulnerability to infections [7]. Moreover, IDA places children at elevated risk of mortality, since anemia contributes to roughly 20% of all maternal deaths [8]. Research indicates that women of reproductive age affected by IDA may face diminished work capacity, reduced physical performance, and a lower overall quality of life [9]. Pregnant women suffering from IDA confront an even higher risk of complications, including low birth weight, premature delivery, and maternal mortality. 10]. Moreover, IDA has been linked to adverse consequences for maternal mental health, such as postpartum depression [11]. IDA carries considerable economic consequences owing to its effects on human productivity, healthcare expenditures, and overall quality of life. According to estimates from the World Health Organization, the annual loss of productivity attributable to IDA amounts to roughly US $22.4 billion [12]. In addition,
Hussein Naji Abdullah Alshammari Directive Publications 2026 healthcare systems across the globe encounter major financial burdens from the costs tied to diagnosing, treating, and managing IDA [13]. Among the diverse efforts to alleviate IDA, a range of interventions has been developed, encompassing iron supplementation, food fortification, and dietary diversification [14] Advocacy for iron supplementation has been particularly pronounced, especially within populations at elevated risk, such as pregnant women and young children. Nevertheless, this intervention is not without possible disadvantages, as documented adverse effects extend from gastrointestinal issues to an increased vulnerability to infectious diseases [15]. The fortification of staple foods, including wheat flour and rice, with iron has been broadly recognized as an effective means of lowering the prevalence of IDA across numerous countries. [16] However, the effectiveness of this approach depends on the bio accessible iron compounds utilized and is affected by other dietary components that influence iron absorption [17]. Encouraging a varied diet, promoting the consumption of iron-rich foods, and incorporating dietary components that enhance iron absorption offers an alternative pathway in the fight against IDA [18]. This approach has proven successful in particular settings, particularly when combined with additional interventions.[19] Nevertheless, the effectiveness of dietary diversification is often constrained by barriers including food insecurity, deeply rooted cultural dietary practices, and limited availability of diverse food resources [10]. Addressing and surmounting obstacles to the deployment of IDA remediation strategies is essential, as these challenges encompass insufficient financial resources, inadequate health infrastructures, and weak surveillance and assessment mechanisms [11]. Moreover, tackling the underlying determinants of iron deficiency such as economic hardship, food insecurity, and constrained access to health care, is necessary to achieve sustained progress in reducing the global IDA burden [12-15]. A multispectral approach can strengthen the effectiveness of IDA countermeasures, and this approach depends on collaboration among diverse stakeholders, including governmental bodies, civil society organizations, and the private sector. Joint endeavors, including extensive fortification programs and community-based nutritional initiatives, have contributed substantially to attaining this objective [16]. Furthermore, integrating IDA prevention and management strategies into existing health care structures, such as maternal and child health services, could enable more efficient use of resources and enhance both the reach and the effectiveness of these interventions [17-20]. In expanding comprehension of the molecular and genetic underpinnings of IDA has driven the emergence of groundbreaking therapeutic approaches. Investigations into hepcidin, a principal regulator of iron homeostasis within the body, have led to the development of hepcidin antagonists. Such agents may potentially act as efficacious therapies for IDA, enhancing the health of individuals afflicted by this condition [21-25]. Precision nutrition interventions customized to an individual's genetic profile have acquired significance owing to the emphasis placed on assimilation and metabolism [26-27]. IDA, Diagnostic Approaches The standard methods conventionally used to diagnose IDA depend on the careful assessment of hematologic indices, serum iron measurements, and iron deposition in the bone marrow.[14] Hematologic indices, including hemoglobin concentration, mean corpuscular volume (MCV), and mean corpuscular hemoglobin (MCH), are routinely measured to identify the presence of anemia and to classify its phenotype as microcytic, normocytic, or macrocytic.[28-30] However, depending on these parameters alone may not be enough to determine the cause of anemia, nor do they consistently reflect an individual's iron reserve status [31-32]. Indicators of iron status in serum, particularly ferritin, transferrin saturation (TSAT), and the soluble transferrin receptor (STfR), function as more refined measures of iron homeostasis [33]. Since serum ferritin is intimately associated with the iron content of bone marrow, it is regarded as the foremost indicator for evaluating the body's iron stores and is conventionally considered the reference standard [34]. Nevertheless, the interpretive usefulness of ferritin can be distorted by unrelated conditions, including inflammatory states, infectious diseases, and hepatic pathologies, which may confound the evaluation of iron status [35]. TSAT offers an indication of the balance between iron supply and demand, whereas STfR concentrations reveal the functional iron deficit occurring within erythropoiesis [36]. Nonetheless, the diagnostic accuracy of these indices is not absolute, as their sensitivity and specificity may be diminished by diverse factors, including inflammatory processes and renal function [37-38]. The definitive evaluation of IDA by directly assessing bone marrow iron content via aspiration and subsequent histological staining is regarded as the gold standard diagnostic approach [39]. Nevertheless, the invasive nature of this procedure entails several limitations, such as the need for specialized equipment and trained personnel, the possibility of patient discomfort, and the associated risk of procedural complications.↻ In addition, the assessment of bone marrow iron content is not immune to inter-observer variability, and its diagnostic conclusiveness for IDA may be ambiguous [36,40]. The intrinsic shortcomings of these standard diagnostic approaches for IDA have substantial consequences for clinical practice as well as public health
Directive Publications Hussein Naji Abdullah Alshammari policy. Erroneous diagnoses, or postponements in reaching an accurate diagnosis, may give rise to inadequate patient management, rising healthcare costs, and missed pivotal opportunities to apply effective therapeutic interventions [20, 32]. Furthermore, reliance on invasive diagnostic methods such as bone marrow aspiration can intensify health-care inequities, especially in settings where resources are limited. The current research trajectory into iron metabolism and the pathophysiology underlying IDA has set the stage for developing novel diagnostic methodologies. Identifying hepcidin as a pivotal regulator in iron homeostasis has incited interest in its application as a biomarker for IDA [41]. Correlations between hepcidin levels and iron status offer insights into anemia’s etiology, whether due to iron scarcity or inflammatory processes [42]. However, establishing hepcidin as a diagnostic tool necessitates the development of standardized measurement protocols and the corroboration of its clinical pertinence through rigorous research [43]. IDA may be identified by means of several approaches, among them invasive procedures. Nonetheless, noninvasive imaging modalities, for instance magnetic resonance imaging and quantitative susceptibility mapping, are likewise applicable for the detection of IDA. Such imaging modalities have demonstrated promise in determining iron distribution and concentration throughout tissues without the need for any invasive procedures [44-45]. In spite of this potential, these technologies have not yet been universally implemented in standard IDA diagnostics, owing to concerns regarding cost, accessibility, and the necessity of thorough validation [46]. Nonetheless, the use of these imaging techniques in routine IDA diagnosis continues to be constrained by cost, availability, and the requirement for additional validation field [47]. The advent of omits technologies spanning genomics, proteomics, and metabolomics – heralds a transformative epoch in diagnosing IDA, facilitating a nuanced delineation of the molecular architectures orchestrating the disorder.[48] These investigative modalities offer the potential to unveil novel biomarkers and molecular signifiers emblematic of IDA, thus propelling diagnostic procedures toward greater precision and personalization [49]. Exemplifying this, proteomic analysis has surfaced a cadre of proteins germane to iron metabolism and erythropoiesis, whose altered expression in IDA patients underscores their diagnostic significance [50]. Complementarily, metabolomic assessments have discerned variations in the metabolic spectra of individuals with IDA, paving the way for these alterations to be harnessed as diagnostic and prognostic indices. Notwithstanding the promising course of these emerging diagnostic methods, a range of obstacles remains to be addressed prior to their widespread adoption in clinical and public health settings. Such barriers encompass the excessive expenses linked to omics and advanced imaging technologies, the requirements for standardizing protocols and reference standards, as well as the ethical and privacy issues pertinent to the use of genomic data [51]. Furthermore, the effective incorporation of these novel diagnostic instruments into conventional medical practice demands a collaborative endeavor involving a broad group of stakeholders, including the research community, clinicians, and policymakers, to guarantee that these developments are equitable, economical, and suitable across diverse health-care contexts [52]. HEMOGLOBIN CONTENT AS A PROMISING BIOMARKER Reticulocytes, the immature precursors of mature erythrocytes, are released from the bone marrow and have a higher hemoglobin concentration than their mature counterparts [53]. The reticulocyte hemoglobin content (CHr) measure quantifies the amount of hemoglobin contained within reticulocytes, thus furnishing an indicator of iron availability at the level of erythropoiesis and of iron adequacy for hemoglobin synthesis during erythropoiesis.[38] Because reticulocytes persist only briefly in the bloodstream, approximately 1–2 days, CHr provides a more current and dynamic evaluation of iron status than do conventional hematologic parameters and serum iron indices [54-55]. Within today's scientific context, efforts to discover new biomarkers that could improve the diagnosis and treatment of IDA have grown more intense. Among these candidates, the (CHr, Ret-He, or MCHr) has emerged as a notable biomarker, especially capable of differentiating IDA from anemia of inflammation [56-60]. This part of the review will examine the benefits of CHr, referred to throughout this review as CHr, as a tool for diagnosis and prognosis, along with its clinical uses, and the possible obstacles and future directions in this area. Numerous investigations have confirmed the clinical utility of CHr in the diagnosis and management of IDA. It demonstrates considerable sensitivity and specificity in detecting iron deficiency across varied demographic groups, including children, adults, and pregnant women [59, 61-62]. In contrast to serum ferritin, the levels of which can be distorted by inflammation, infection, and hepatic disease, CHr is less vulnerable to these confounding factors, thereby potentially providing a more accurate indicator of iron status in patients with coexisting inflammatory or infectious conditions. Moreover, the prognostic utility of CHr within IDA management has been recognized. It functions as a reliable means of monitoring the hematologic response to iron supplementation and as a basis for modifying iron dosages across the entire course of treatment [58,63-66]. CHr has likewise been proposed as an early indicator of iron-restricted erythropoiesis (IRE) in patients receiving erythropoiesis- 2026
Hussein Naji Abdullah Alshammari Directive Publications 2026 stimulating agents (ESAs) for anemia linked to chronic kidney disease, cancer, or other chronic conditions [67]. The range of clinical utility associated with CHr extends beyond the diagnosis and treatment of IDA. CHr has come to be acknowledged as an essential parameter for evaluating functional iron deficiency among patients afflicted with heart failure, thereby aiding in the distinction between genuine ID and the anemia of inflammation [68]. Furthermore, the capacity of CHr to serve as a biomarker for the early identification of iron overload in persons with hereditary hemochromatosis and other iron-loading disorders has been suggested [69]. Future investigations ought to address these obstacles and more closely examine the clinical value of CHr as a biomarker for IDA. Extensive, multicenter studies are necessary to establish standardized reference values and thresholds for CHr that encompass diverse populations and age groups. At the same time, efforts should be directed toward improving the availability and cost-effectiveness of CHr testing, particularly in resource-limited settings where accurate and timely IDA diagnosis is urgently required. The development of point-of-care testing (POCT) devices for CHr may alleviate many existing difficulties by enabling rapid, economical, and decentralized IDA assessments [70- 73]. Advances in microfluidics, biosensing, and digital health technologies have laid the groundwork for portable POCT devices capable of measuring CHr and other hematologic parameters with minimal sample volume and equipment demands [74]. Such devices hold the potential to transform IDA diagnosis and treatment, enabling healthcare practitioners to make immediate, well-informed decisions about iron supplementation, dosage adjustment, or additional diagnostic workup [75]. ADVANTAGES OF HEMOGLOBIN CONTENT IN RETICULOCYTES Early detection of deficiency The CHr emerges as an index of central importance in the early identification of ID and IDA, thereby providing the rationale for timely intervention and the prevention of sequelae associated with untreated iron deficits. CHr measures the hemoglobin content of reticulocytes, furnishing a rapid and dynamic indicator of iron status that surpasses conventional hematological parameters and serum iron indices with respect to immediacy [76]. Given the brief circulatory lifespan of reticulocytes, generally 1–2 days, their hemoglobin content reflects emerging shifts in iron availability for erythropoiesis, preceding the appearance of overt anemia [77]. Empirical findings emphasize the enhanced sensitivity and specificity of CHr in identifying the onset of ID and IDA. Work by Ullrich et al. confirms that CHr surpasses established hematological indicators, including MCV and MCH, in identifying early iron deficiency in healthy infants [78]. In a similar vein, Mast et al. demonstrated that CHr displays greater sensitivity and specificity in diagnosing IDA among adults when compared with serum ferritin, TSAT, and red blood cell indices. Detect functional iron deficiency CHr offers a foundational advantage through its ability to identify functional ID, a condition in which iron is insufficiently assimilated for erythropoiesis despite normal or elevated total body iron stores. This condition is commonly observed within the setting of chronic diseases such as chronic kidney disease, heart failure, and various inflammatory states. Conventional indices of iron status are frequently obscured by the inflammatory response and coexisting disorders, thus rendering the diagnosis of functional iron deficiency more difficult. Evidence indicates that CHr is reliable as an indicator of functional ID across a range of clinical scenarios. Among the chronic kidney disease patient population, CHr has been validated as a more accurate measure of IRE than serum ferritin and TSAT, particularly in the setting of inflammatory processes or concurrent administration of ESAs [7 9-81] In individuals with heart failure, CHr effectively distinguishes between genuine iron deficiency and anemia of inflammation, thereby guiding the management strategy for such patients [82]. Furthermore, CHr has been proposed as an effective instrument for monitoring responses to iron therapy among diverse groups, including pediatric cohorts, expectant mothers, and patients with chronic illnesses. Its dynamic character permits a prompt assessment of the efficacy of iron supplementation, thereby enabling clinicians to adjust treatment plans and dosages with greater speed than traditional iron status measures would allow. Reticulocyte Hemoglobin Content A salient merit of CHr as a biomarker for IDA is its relative insusceptibility to inflammatory processes, a trait not shared by other iron metrics such as serum ferritin and TSAT [83]. Inflammatory responses, precipitated by a spectrum of acute and chronic disorders, can perturb iron homeostasis, thereby obfuscating the assessment of traditional iron indices. Cytokines, particularly interleukin-6, are known to increase hepcidin synthesis, culminating in diminished iron absorption and mobilization from stores, leading to functional iron deficiency. Assessment of iron availability for erythropoiesis By offering a more direct and dynamic indicator of iron's availability for erythropoiesis, CHr may enhance the diagnosis and therapeutic management of IDA and its related
Directive Publications Hussein Naji Abdullah Alshammari conditions. Empirical studies have demonstrated that CHr exhibits greater sensitivity and specificity as a marker of iron- limited erythropoiesis than conventional iron indices. This is particularly relevant for individuals receiving ESA treatment for anemia associated with chronic kidney disease, cancer, or other chronic health conditions [84]. Research corroborates the effectiveness of CHr in assessing iron status during concurrent inflammatory or infectious conditions. For instance, in pediatric research conducted by Mäkelä et al., CHr emerged as a more precise indicator of iron deficiency than serum ferritin and TSAT in acute infections [85]. Similarly, work by Dignass et al. showed that CHr’s reliability as an iron status marker was less compromised by inflammatory states than serum ferritin in patients with anemia of chronic disease, thereby offering a more dependable measure of iron status in this demographic. CHr provides an improved assessment of iron bioavailability for erythropoiesis relative to conventional iron indices by quantitatively measuring hemoglobin within reticulocytes, thus reflecting the status of iron reserves in erythropoietic tissues [86]. Traditional iron metrics such as serum ferritin and TSAT provide indirect evaluations of iron status, which may not reliably reflect iron's availability for erythropoietic processes, especially in cases of functional iron deficiency or concurrent inflammatory conditions. Therapy and Monitoring Treatment Response The CHr plays a central role in coordinating iron therapy and in monitoring therapeutic outcomes among individuals with IDA. Because it can promptly mirror shifts in the iron available for erythropoiesis, CHr permits a more expedited assessment of therapeutic efficacy than conventional iron indices, thereby supporting timely modifications to iron dosage and treatment approaches [87]. Research has confirmed the effectiveness of CHr in guiding iron therapy and evaluating therapeutic responses among diverse demographic groups, such as children, adults, and pregnant women. For example, Neef et al. documented that iron therapy guided by CHr produced a more rapid and sustained therapeutic response in pediatric patients with IDA than methods depending on serum ferritin and TSAT. Almashjary et al. have recognized CHr as a better marker than hemoglobin for detecting the swift improvement following iron therapy within one week among adult subjects with ID and IDA. Likewise, an analytical review by Govindappagari and Burwick has shown that iron therapy centered on CHr enhances the efficacy of iron supplementation in pregnant women with IDA, while simultaneously reducing the need for intravenous iron interventions [88]. In addition, CHr has demonstrated value in tracking the response to iron therapy among patients who receive ESAs for the management of anemia in the setting of chronic conditions such as chronic kidney disease or cancer [77- 81, 89] By providing a more prompt and dynamic indicator of iron availability for erythropoiesis, CHr helps health-care professionals to adjust the dosing and administration of ESAs, thus reducing possible adverse effects and improving overall therapeutic outcomes. CONCLUSION IDA constitutes a prevalent health condition affecting a considerable segment of the global population. In recent times, the adoption of the CHr test has demonstrated encouraging outcomes in the diagnosis and management of this condition. CHr serves as a sensitive and specific indicator of iron deficiency, and its clinical effectiveness underscores its capacity to raise care standards and enhance patient outcomes. Notwithstanding its promise, several obstacles remain regarding the use of CHr within existing diagnostic and treatment protocols. Additional research is required to address these obstacles and to formulate explicit guidelines for incorporating CHr into routine clinical practice. Through deepening our comprehension of CHr and its applications, we can reduce the global burden of IDA and improve the well-being of affected populations. The integration of CHr into existing frameworks holds the promise of enhancing the identification and management of iron deficiency along with its related disorders. This will allow health-care providers to make better-informed decisions regarding patient care and treatment options, thereby producing improved health outcomes for patients. On the whole, CHr possesses considerable potential to transform the manner in which we diagnose and manage IDA, and additional research in this domain is essential for enhancing patient care and health outcomes. Conflict of Interest The authors declare no conflict of interest REFERENCES 1. De Benoist B World Health Organization, Centers for Disease Control and Prevention (U. S.). Worldwide Prevalence of Anaemia 1993-2005 of: WHO Global Database of Anaemia. Geneva: World Health Organization; 2008. 2. Warner MJ, Kamran MT. Iron deficiency anemia. StatPearls. Treasure Island, FL: United States of America; 2023. 3. Abbaspour N, Hurrell R, Kelishadi R. Review on iron and its importance for human health. J Res Med Sci 2014; 19:164–74. 2026
Hussein Naji Abdullah Alshammari Directive Publications 2026 4. Kassebaum NJ, Jasrasaria R, Naghavi M, Wulf SK, Johns N, Lozano R, et al. Asystematic analysis of global anemia burden from 1990 to 2010. Blood 2014; 123:615–24. 5. Miller JL. Iron deficiency anemia: A common and curable disease. Cold Spring Harb Perspect Med 2013; 3:a011866 6. Balarajan Y, Ramakrishnan U, Ozaltin E, Shankar AH, Subramanian SV. Anaemia in low-income and middle- income countries. Lancet 2011; 378:2123–35. 7. Georgieff MK. Iron deficiency in pregnancy. Am J Obstet Gynecol 2020; 223:516–24. 8. Kavle JA, Stoltzfus RJ, Witter F, Tielsch JM, Khalfan SS, Caulfield LE. Association between anaemia during pregnancy and blood loss at and after delivery among women with vaginal births in Pemba Island, Zanzibar, Tanzania. J Health Popul Nutr 2008; 26:232–40. 9. Haas JD, Brownlie T 4th. Iron deficiency and reduced work capacity: A critical review of the research to determine a causal relationship. J Nutr 2001; 131:676S–88S. 10. Darnton-Hill I, Mkparu UC. Micronutrients in pregnancy in low- and middle-income countries. Nutrients 2015; 7:1744–68 11. Corwin EJ, Murray-Kolb LE, Beard JL. Low hemoglobin level is a risk factor for postpartum depression. J Nutr 2003; 133:4139–42. 12. World Health Organization. Guideline: Daily Iron and Folic Acid Supplementation in Pregnant Women. Geneve, Switzerland: World Health Organization; 2012. 13. Gupta PM, Hamner HC, Suchdev PS, Flores-Ayala R, Mei Z. Iron status of toddlers, nonpregnant females, and pregnant females in the United States. Am J Clin Nutr 2017; 106:1640S–6S. 14. Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L. Iron deficiency anaemia. Lancet 2016; 387:907–16 15. Sazawal S, Black RE, Ramsan M, Chwaya HM, Stoltzfus RJ, Dutta A, et al. Effects of routine prophylactic supplementation with iron and folic acid on admission to hospital and mortality in preschool children in a high malaria transmission setting: community-based, randomised, placebo-controlled trial. Lancet 2006; 367:133–43. 16. Hurrell R, Egli I. Iron bioavailability and dietary reference values. Am J Clin Nutr 2010; 91:1461S–7S. 17. Hurrell R. How to ensure adequate iron absorption from iron-fortified food. Nutr Rev 2002; 60:S7–15. 18. Gibson RS, Raboy V, King JC. Implications of phytate in plant-based foods for iron and zinc bioavailability, setting dietary requirements, and formulating programs and policies. Nutr Rev 2018; 76:793–804 19. Finkelstein JL, Haas JD, Mehta S. Iron-biofortified staple food crops for improving iron status: A review of the current evidence. Curr Opin Biotechnol 2017; 44:138– 45. 20. McLean E, Cogswell M, Egli I, Wojdyla D, de Benoist B. Worldwide prevalence of anaemia, WHO vitamin and mineral nutrition information system, 1993-2005. Public Health Nutr 2009; 12:444–54 21. Stevens GA, Finucane MM, De-Regil LM, Paciorek CJ, Flaxman SR, Branca F, et al. Global, regional, and national trends in haemoglobin concentration and prevalence of total and severe anaemia in children and pregnant and non-pregnant women for 1995-2011: A systematic analysis of population-representative data. Lancet Glob Health 2013; 1:e16–25 22. Zimmermann MB, Hurrell RF. Nutritional iron deficiency. Lancet 2007; 370:511–20 23. Allen L, Benoist B, Dary O, Hurrell R. WHO/FAO Guidelines on Food Fortification with Micronutrients. Geneva: WHO; 2006. 24. Sitecontrol. Improving Child Nutrition: The Achievable Imperative for Global Progress. Geneva: UNICEF DATA; 2013 25. Ganz T. Hepcidin and iron regulation, 10 years later. Blood 2011; 117:4425–33 26. Arezes J, Jung G, Gabayan V, Valore E, Ruchala P, Gulig PA, et al. Hepcidin-induced hypoferremia is a critical host defense mechanism against the siderophilic bacterium Vibrio vulnificus. Cell Host Microbe 2015; 17:47–57 27. Fairweather-Tait SJ, Jennings A, Harvey LJ, Berry R, Walton J, Dainty JR. Modeling tool for calculating dietary iron bioavailability in iron-sufficient adults. Am J Clin Nutr 2017; 105:1408–14
Directive Publications Hussein Naji Abdullah Alshammari 28. Hallberg L, Brune M, Erlandsson M, Sandberg AS, Rossander-Hultén L. Calcium: Effect of different amounts on nonheme- and heme-iron absorption in humans. Am J Clin Nutr 1991; 53:112–9 29. Killip S, Bennett JM, Chambers MD. Iron deficiency anemia. Am Fam Physician 2007; 75:671–8 30. World Health Organization. Haemoglobin Concentrations for the Diagnosis of Anaemia and Assessment of Severity. Geneva: World Health Organization; 2011. 31. Urrechaga E, Borque L, Escanero JF. Erythrocyte and reticulocyte indices in the assessment of erythropoiesis activity and iron availability. Int J Lab Hematol 2013; 35:144–9. 32. Camaschella C. Iron-deficiency anemia. N Engl J Med 2015; 372:1832–43. 33. Joint World Health Organization/Centers for Disease Control and Prevention Technical Consultation on the Assessment of Iron Status at the Population Level (20048239: 34. Geneva S. Assessing the iron status of populations: Including Literature Reviews: Report of a Joint World Health Organization/Centers for Disease Control and Prevention Technical Consultation on the Assessment of Iron Status at the Population Level, Geneva, Switzerland, 6-8 April 2004. World Health Organization 2007 35. Wish JB. Assessing iron status: Beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 2006; 1 Suppl 1:S48. 36. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352:1011–23 37. Thomas C, Thomas L. Anemia of chronic disease: Pathophysiology and laboratory diagnosis. Lab Hematol 2005; 11:14–23 38. Skikne BS, Flowers CH, Cook JD. Serum transferrin receptor: A quantitative measure of tissue iron deficiency. Blood 1990; 75:1870–6 39. Mast AE, Blinder MA, Dietzen DJ. Reticulocyte hemoglobin content. Am J Hematol 2008; 83:307–10 40. Cook JD. Diagnosis and management of iron-deficiency anaemia. Best Pract Res Clin Haematol 2005; 18:319–32 41. Bain BJ. Bone marrow trephine biopsy. J Clin Pathol 2001; 54:737–42 42. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003; 102:783–8 43. Kemna EH, Tjalsma H, Podust VN, Swinkels DW. Mass spectrometry-based hepcidin measurements in serum and urine: Analytical aspects and clinical implications. Clin Chem 2007; 53:620–8 44. Kroot JJ, Laarakkers CM, Geurts-Moespot AJ, Grebenchtchikov N, Pickkers P, van Ede AE, et al. Immunochemical and mass-spectrometry-based serum hepcidin assays for iron metabolism disorders. Clin Chem 2010; 56:1570–9 45. Wood JC. Magnetic resonance imaging measurement of iron overload. Curr Opin Hematol 2007; 14:183–90 46. Haacke EM, Tang J, Neelavalli J, Cheng YC. Susceptibility mapping as a means to visualize veins and quantify oxygen saturation. J Magn Reson Imaging 2010; 32:663– 76 47. Ghugre NR, Wood JC. Relaxivity-iron calibration in hepatic iron overload: Probing underlying biophysical mechanisms using a Monte Carlo model. Magn Reson Med 2011; 65:837–47 48. Daugherty AM, Raz N. Appraising the role of iron in brain aging and cognition: Promises and limitations of MRI methods. Neuropsychol Rev 2015; 25:272–87 49. Muckenthaler MU, Rivella S, Hentze MW, Galy B. A red carpet for iron metabolism. Cell 2017; 168:344–61 50. Pantopoulos K, Porwal SK, Tartakoff A, Devireddy L. Mechanisms of mammalian iron homeostasis. Biochemistry 2012; 51:5705–24 51. Zhang X, Jin M, Wu H, Nadasdy T, Nadasdy G, Harris N, et al. Biomarkers of lupus nephritis determined by serial urine proteomics. Kidney Int 2008; 74:799–807 52. Esteva A, Robicquet A, Ramsundar B, Kuleshov V, DePristo M, Chou K, et al. Aguide to deep learning in healthcare. Nat Med 2019; 25:24–9 2026
Hussein Naji Abdullah Alshammari Directive Publications 2026 53. Miotto R, Wang F, Wang S, Jiang X, Dudley JT. Deep learning for healthcare: Review, opportunities and challenges. Brief Bioinform 2018; 19:1236–46 54. Asare JW, Appiahene P, Donkoh ET, Dimauro G. Iron deficiency anemia detection using machine learning models: A comparative study of fingernails, palm and conjunctiva of the eye images. Eng Rep 2023; 5:e12667 55. Kratz A, Lee SH, Zini G, Riedl JA, Hur M, Machin S, et al. Digital morphology analyzers in hematology: ICSH review and recommendations. Int J Lab Hematol 2019; 41:437–47.7 56. Dogan S, Turkoglu I. Iron-Deficiency anemia detection from hematology parameters by using decision trees 2008 57. Mathur S, Sutton J. Personalized medicine could transform healthcare. Biomed Rep 2017; 7:3–5 58. Pascual J, Attard G, Bidard FC, Curigliano G, De Mattos- Arruda L, Diehn M, et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: A report from the ESMO Precision Medicine Working Group. Ann Oncol 2022; 33:750–68 59. Brugnara C, Laufer MR, Friedman AJ, Bridges K, Platt O. Reticulocyte hemoglobin content (CHr): Early indicator of iron deficiency and response to therapy. Blood 1994; 83:3100–1 60. Brugnara C, Schiller B, Moran J. Reticulocyte hemoglobin equivalent (Ret He) and assessment of iron-deficient states. Clin Lab Haematol 2006; 28:303–8 61. Thomas C, Thomas L. Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem 2002; 48:1066–76 62. Urrechaga E, Borque L, Escanero JF. The role of automated measurement of RBC subpopulations in differential diagnosis of microcytic anemia and ?-thalassemia screening. Am J Clin Pathol 2011; 135:374–9 63. Ullrich C, Wu A, Armsby C, Rieber S, Wingerter S, Brugnara C, et al. Screening healthy infants for iron deficiency using reticulocyte hemoglobin content. JAMA 2005; 294:924–30 64. Fishbane S, Galgano C, Langley RC Jr, Canfield W, Maesaka JK. Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney Int 1997; 52:217–22 65. Almashjary MN, Barefah AS, Bahashwan S, Ashankyty I, ElFayoumi R, Alzahrani M, et al. Reticulocyte hemoglobin-equivalent potentially detects, diagnoses and discriminates between stages of iron deficiency with high sensitivity and specificity. J Clin Med 2022; 11:5675 66. Toki Y, Ikuta K, Kawahara Y, Niizeki N, Kon M, Enomoto M, et al. Reticulocyte hemoglobin equivalent as a potential marker for diagnosis of iron deficiency. Int J Hematol 2017; 106:116–25 67. Uçar MA, Falay M, Dağdas S, Ceran F, Urlu SM, Özet G. The importance of RET-He in the diagnosis of iron deficiency and iron deficiency anemia and the evaluation of response to oral iron therapy. J Med Biochem 2019; 38:496–502 68. Beguin Y, Clemons GK, Pootrakul P, Fillet G. Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. Blood 1993; 81:1067–76 69. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010; 31:1872–80 70. Adams PC, Reboussin DM, Barton JC, McLaren CE, Eckfeldt JH, McLaren GD, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005; 352:1769–78 71. Brugnara C, Zurakowski D, DiCanzio J, Boyd T, Platt O. Reticulocyte hemoglobin content to diagnose iron deficiency in children. JAMA 1999; 281:2225–30 72. Brugnara C. Reticulocyte cellular indices: A new approach in the diagnosis of anemias and monitoring of erythropoietic function. Crit Rev Clin Lab Sci 2000; 37:93–130 73. Kruk ME, Gage AD, Arsenault C, Jordan K, Leslie HH, Roder-DeWan S, et al. High-quality health systems in the Sustainable Development Goals era: Time for a revolution. Lancet Glob Health 2018; 6:e1196–252
Directive Publications Hussein Naji Abdullah Alshammari 74. Padma Behera P, Kumar N, Kumari M, Kumar S, Mondal PK, Arun RK. Integrated microfluidic devices for point- of-care detection of bio-analytes and disease. Sens Diagn 2023; 2:1437–59 75. Grigorev GV, Lebedev AV, Wang X, Qian X, Maksimov GV, Lin L. Advances in microfluidics for single red blood cell analysis. Biosensors (Basel) 2023; 13:117 76. Batchelor EK, Kapitsinou P, Pergola PE, Kovesdy CP, Jalal DI. Iron deficiency in chronic kidney disease: Updates on pathophysiology, diagnosis, and treatment. J Am Soc Nephrol 2020; 31:456–68 77. Nemeth E, Ganz T. Anemia of inflammation. Hematol Oncol Clin North Am 2014; 28:671–81. vi 78. Karunarathne P, Kulathilake C, Wijesiriwardena I, Hewageegana A, Marasinghe A. Evaluation of iron status by reticulocyte haemoglobin content (Chr) in chronic kidney disease patients on haemodialysis and erythropoietin. Indian J Hematol Blood Transfus 2022; 38:359–65 79. Maconi M, Cavalca L, Danise P, Cardarelli F, Brini M. Erythrocyte and reticulocyte indices in iron deficiency in chronic kidney disease: Comparison of two methods. Scand J Clin Lab Invest 2009; 69:365–70 80. Gao Z, Hu Y, Gao Y, Ma X, Hu Z. The association of hepcidin, reticulocyte hemoglobin equivalent and anemia-related indicators on anemia in chronic kidney disease. Medicine (Baltimore) 2023; 102:e33558 81. Cases A, de Sequera P, Quiroga B, Puchades MJ, Martin- Rodriguez L, Gorriz JL, et al. Reticulocyte hemoglobin content and iron therapy in chronic kidney disease: Reply of the Anemia group of the Spanish Society of Nephrology. Nefrologia (Engl Ed) 2023; 43:651–52 82. Garzia M, Di Mario A, Ferraro E, Tazza L, Rossi E, Luciani G, et al. Reticulocyte hemoglobin equivalent: An indicator of reduced iron availability in chronic kidney diseases during erythropoietin therapy. Lab Hematol 2007; 13:6–11 83. Tahara S, Naito Y, Okuno K, Yasumura S, Horimatsu T, Ohno J, et al. Clinical utility of reticulocyte hemoglobin equivalent in patients with heart failure. Sci Rep 2022; 12:13978 84. Mäkelä E, Takala TI, Suominen P, Matomäki J, Salmi TT, Rajamäki A, et al. Hematological parameters in preterm infants from birth to 16 weeks of age with reference to iron balance. Clin Chem Lab Med 2008; 46:551–7
85. Dignass A, Farrag K, Stein J. Limitations of serum ferritin in diagnosing iron deficiency in inflammatory conditions. Int J Chronic Dis 2018 2018;9394060
86. Gelaw Y, Woldu B, Melku M. The role of reticulocyte hemoglobin content for diagnosis of iron deficiency and iron deficiency anemia, and monitoring of iron therapy: A literature review. Clin Lab 2019; 65:12. [doi: 10.7754/ Clin. Lab. 2019 190315]
87. Neef V, Schmitt E, Bader P, Zierfuß F, Hintereder G, Steinbicker AU, et al. The reticulocyte hemoglobin equivalent as a screening marker for iron deficiency and iron deficiency anemia in children. J Clin Med 2021; 10:3506
88. Govindappagari S, Burwick RM. Treatment of iron deficiency anemia in pregnancy with intravenous versus oral iron: Systematic review and meta-analysis. Am J Perinatol 2019; 36:366–76
89. Brugnara C, Colella GM, Cremins J, Langley RC Jr, Schneider TJ, Rutherford CJ, et al. Effects of subcutaneous recombinant human erythropoietin in normal subjects: Development of decreased reticulocyte hemoglobin content and iron-deficient erythropoiesis. J Lab Clin Med 1994; 123:660–7 2026
This is a text version generated from the article. For the formatted version of record (with original tables & figures), download the PDF →